Researchers have developed a new class of drugs that is able to cross the blood-brain barrier. The technology has been licensed to the startup Teleport Pharmaceuticals.
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease
May 17, 2021 07:59 ET | Source: PharmaTher Holdings Ltd. PharmaTher Holdings Ltd. Vancouver, British Columbia, CANADA
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Investigational New Drug (“IND”) application to proceed with a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (“LID-PD”). PharmaTher expects to begin enrolling patients in the Phase 2 clinical trial in Q3-2021. Assuming the Phase 2 clinical trial is positive, the Company will request a meeting with the FDA to discuss
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson’s Disease
December 10, 2020 07:00 ET | Source: Newscope Capital Corporation Newscope Capital Corporation Vancouver, British Columbia, CANADA
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has been granted a Pre-Investigational New Drug (“PIND”) meeting with the U.S. Food and Drug Administration (“FDA”) for the clinical development of ketamine in Parkinson’s disease and its proposed Phase 2 clinical study for ketamine in the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (“LID-PD”).